Small molecules continue to play a major part in pharmaceutical development, but increasing molecular complexity, accelerated timelines, and evolving manufacturing and regulatory requirements are creating new challenges for the industry.

In this GEN Podcast—part 2 in a 3-part series—a trio of experts from SK Pharmteco discuss how CDMOs are helping biopharma companies navigate critical areas including scale-up, technology transfer, advanced manufacturing, automation, sustainability, the emergence of AI, and supply chain reliability. The discussion explores practical strategies for improving development efficiency while supporting quality, scalability, and long-term commercial success.

Podcast Guests:

Steve Barr, PhD
Head of Small Molecule Business Unit
and VP Global Alliances
SK pharmteco

Darryl Ratty
Executive Director of Global ESG
ESG (Environmental, Social and Governance)
SK pharmteco

Bill DuBay
Vice President,
Global Research and Development
SK pharmteco

Produced with support from: